Viagra Ingredient Offers Hope for Children with Leigh Syndrome

Sildenafil, the active ingredient in Viagra, is showing unexpected promise as a potential treatment for Leigh syndrome, a rare and devastating childhood metabolic disorder. Researchers have observed improvements in patients with this currently untreatable condition, offering a glimmer of hope for families affected by this disease.

Understanding Leigh Syndrome

Leigh syndrome is a congenital, progressive neurological disorder that typically manifests in infancy or early childhood. It results from defects in cellular energy production, impacting both the brain and muscles. Symptoms include epileptic seizures, muscle weakness, paralysis, and cognitive impairment. The disease significantly reduces life expectancy, and currently, there are no approved medications to treat it. It affects approximately one in 36,000 children.¹

The Unexpected Discovery: Sildenafil’s Role

A pilot study involving six patients with Leigh syndrome, aged between 9 months and 38 years, revealed encouraging results with sildenafil treatment. Patients demonstrated improvements in muscle strength, and some experienced a reduction or elimination of neurological symptoms. Notably, patients also recovered more quickly from metabolic crises – episodes where energy metabolism becomes overwhelmed, rapidly worsening the disease.³

One child treated with sildenafil saw their walking distance increase tenfold, from 500 to 5,000 meters. In other patients, the therapy suppressed monthly metabolic crises, and epileptic seizures were eliminated.³

How Sildenafil Works: Laboratory Findings

The research team employed an innovative approach, utilizing brain organoids – three-dimensional replicas of the brain grown from patient stem cells – to mimic the clinical picture of Leigh syndrome.¹³ These organoids were used to screen over 5,500 compounds, identifying sildenafil as a potential therapeutic agent.

Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, corrected mitochondrial membrane potential defects, restored neurodevelopmental pathways, and normalized calcium responses in the organoids.⁴ Further experiments showed that sildenafil stimulated nerve cell growth in the organoids and improved energy metabolism in animal models.³

Research Collaboration and Future Steps

The study was a collaborative effort led by scientists at Charité – Universitätsmedizin Berlin, in conjunction with teams from Heinrich Heine University Düsseldorf (HHU), University Hospital Düsseldorf (UKD), and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Hamburg.¹

The European Medicines Agency (EMA) has granted sildenafil orphan drug status for the treatment of Leigh syndrome, which will streamline the approval process.³ Researchers are now planning a Europe-wide, placebo-controlled clinical trial as part of the SIMPATHIC EU project to confirm these initial findings and potentially pave the way for sildenafil’s approval as a treatment for Leigh syndrome.

Key Takeaways

• Sildenafil shows promise as a potential treatment for Leigh syndrome, a rare and currently untreatable childhood disease.
• Pilot studies have demonstrated improvements in muscle strength, neurological symptoms, and recovery from metabolic crises in patients treated with sildenafil.
• Laboratory research using brain organoids and animal models supports the therapeutic potential of sildenafil.
• A larger, placebo-controlled clinical trial is planned to confirm these findings and seek regulatory approval.